// App-Quantinova.ai

: Responsiveness and the Minimal Clinically Important Difference for HM-PRO in Patients with Hematological Malignancies

Researchers

Presenter

  • Pushpendra Goswami

Principal Investigators

  • Esther Natalie Oliva

  • Tatyana Ionova

  • Sam Salek

Medical Centers

  • School of Life & Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom

  • Division of Hematology, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy

  • University Clinic, St. Petersburg State University and Multinational Center for Quality of Life Research, Saint-Petersburg, Russian Federation

  • University of Hertfordshire, Hatfield, United Kingdom

Locations

  • United Kingdom

  • Italy

  • Russia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Acute lymphoblastic leukemia

  • Chronic Lymphocytic Leukemia

  • Myeloid neoplasms

  • Hematological malignancies

  • Alpha-thalassemia myelodysplasia syndrome

  • Chronic Myelogenous Leukemia

  • Acute myelocytic leukemia

  • Non‐Hodgkin Lymphoma

  • Hodgkin's Lymphoma

  • Multiple Myeloma

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Multicenteric

  • Prospective

  • Cross-Sectional

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved